StockData
BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ

BriaCell Therapeutics Corp.

Financials through Q3 FY2026, quarter ended Apr 30, 2026Last filing: 10-Q on Jun 9, 2026
$3.38−0.02 (-0.59%)

Close on Oct 19, 2026

Market cap
$24.51M
P/E (TTM)
–
Dividend yield
–

BriaCell Therapeutics Corp. revenue by segment

No segment breakdown reported

BriaCell Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.